Diverse signalling by 5-hydroxytryptamine (5-HT) receptors.

Fourteen different receptor subtypes might be regarded as a diversity that is sufficient to accommodate the wide-ranging physiological roles of 5-hydroxytryptamine (5-HT). However, it is becoming clear that, for 5-HT as for other neurotransmitters, the concept of a receptor as a gatekeeper for a specific cellular process or event is too restrictive. Multiple receptor-mediated biochemical cascades can be activated in cells in response to an agonist by a number of mechanisms. Whereas it is well established that different agonists do not necessarily elicit the same magnitude of response, they probably also select between various possible signal transduction pathways. Receptor signalling may be diverse via a single receptor subtype as a consequence of specific agonist-receptor-G protein interactions. 5-HT receptors are even more heterogeneous when one considers that the amino acid sequence of these receptor subtypes may vary from individual to individual, and that there is an increasing number of receptor isoforms due to alternative splicing and RNA editing of 5-HT receptor transcripts. Activation, in particular constitutive, agonist-independent activation, of some of these receptor isoforms has been reported to be altered. This implies that ligands with similar binding affinities may display different pharmacological properties (partial agonist, antagonist, or inverse agonist) versus these receptor isoforms, depending on their activation state. Therefore, intervention with receptor ligands to modify hampered neurotransmission pathways is a difficult task, and one needs to consider the growing evidence of diversity in G protein-coupled receptor signalling.

[1]  A M Krumins,et al.  The stability of the agonist beta2-adrenergic receptor-Gs complex: evidence for agonist-specific states. , 1997, Molecular pharmacology.

[2]  M. Ferrari,et al.  Coronary side-effect potential of current and prospective antimigraine drugs. , 1998, Circulation.

[3]  W. Sadee,et al.  Hydrophobic amino acid in the i2 loop plays a key role in receptor-G protein coupling. , 1993, The Journal of biological chemistry.

[4]  G. Milligan,et al.  Up‐regulation of a constitutively active form of the β 2‐adrenoceptor by sustained treatment with inverse agonists but not antagonists , 1996, FEBS letters.

[5]  D. Goldman,et al.  Agonist-Promoted Down-Regulation and Functional Desensitization in Two Naturally Occurring Variants of the Human Serotonin1A Receptor , 1997, Neuropsychopharmacology.

[6]  H. Bönisch,et al.  Modified ligand binding to the naturally occurring Cys-124 variant of the human serotonin 5-HT1B receptor. , 1999, Pharmacogenetics.

[7]  R. Kohen,et al.  Four 5‐Hydroxytryptamine7 (5‐HT7) Receptor Isoforms in Human and Rat Produced by Alternative Splicing: Species Differences Due to Altered Intron‐Exon Organization , 1997, Journal of neurochemistry.

[8]  G. Milligan,et al.  Regulation of G Protein Activation and Effector Modulation by Fusion Proteins between the Human 5-Hydroxytryptamine1AReceptor and the α Subunit of Gi1α: Differences in Receptor-Constitutive Activity Imparted by Single Amino Acid Substitutions in Gi1α , 1999 .

[9]  P. Albert,et al.  A conserved threonine residue in the second intracellular loop of the 5-hydroxytryptamine 1A receptor directs signaling specificity. , 1997, Molecular pharmacology.

[10]  H. Manji,et al.  A Naturally Occurring Amino Acid Substitution of the Human Serotonin 5‐HT2A Receptor Influences Amplitude and Timing of Intracellular Calcium Mobilization , 1997, Journal of neurochemistry.

[11]  G. Martin,et al.  The structure and signalling properties of 5-HT receptors: an endless diversity? , 1998, Trends in pharmacological sciences.

[12]  T. Kenakin,et al.  Agonist-receptor efficacy. II. Agonist trafficking of receptor signals. , 1995, Trends in pharmacological sciences.

[13]  P. Pauwels 5-HT 1B/D receptor antagonists. , 1997, General pharmacology.

[14]  Y. Sugimoto,et al.  Selective Coupling of Prostaglandin E Receptor EP3D to Gi and Gs through Interaction of α-Carboxylic Acid of Agonist and Arginine Residue of Seventh Transmembrane Domain (*) , 1995, The Journal of Biological Chemistry.

[15]  R. Fischmeister,et al.  The 5‐HT4 receptor antagonist ML10375 inhibits the constitutive activity of human 5‐HT4(c) receptor , 1998, British journal of pharmacology.

[16]  A. Barr,et al.  Agonist-independent activation of Gz by the 5-hydroxytryptamine1A receptor co-expressed in Spodoptera frugiperda cells. Distinguishing inverse agonists from neutral antagonists. , 1997, The Journal of biological chemistry.

[17]  M. Zuscik,et al.  Identification of a Conserved Switch Residue Responsible for Selective Constitutive Activation of the β2-Adrenergic Receptor* , 1998, The Journal of Biological Chemistry.

[18]  S. Rees,et al.  Agonist occupation of an alpha2A-adrenoreceptor-Gi1alpha fusion protein results in activation of both receptor-linked and endogenous Gi proteins. Comparisons of their contributions to GTPase activity and signal transduction and analysis of receptor-G protein activation stoichiometry. , 1998, The Journal of biological chemistry.

[19]  T. Kenakin The classification of seven transmembrane receptors in recombinant expression systems. , 1996, Pharmacological reviews.

[20]  P P Humphrey,et al.  International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). , 1994, Pharmacological reviews.

[21]  Colleen M. Niswender,et al.  RNA Editing of the Human Serotonin 5-Hydroxytryptamine 2C Receptor Silences Constitutive Activity* , 1999, The Journal of Biological Chemistry.

[22]  G. Milligan,et al.  Insights into ligand pharmacology using receptor-G-protein fusion proteins. , 2000, Trends in pharmacological sciences.

[23]  S. Maayani,et al.  Novel actions of inverse agonists on 5-HT2C receptor systems. , 1999, Molecular pharmacology.

[24]  Q. Yang,et al.  Influence of G protein type on agonist efficacy. , 1999, Molecular pharmacology.

[25]  E. sanders-Bush,et al.  Reciprocal binding properties of 5-hydroxytryptamine type 2C receptor agonists and inverse agonists. , 1994, Molecular pharmacology.

[26]  P. Pauwels,et al.  Modulation of 5-HT1A receptor signalling by point-mutation of cysteine351 in the rat Gαo protein , 1999, Neuropharmacology.

[27]  Hui-yu Liu,et al.  Quantitative Analysis of Formyl Peptide Receptor Coupling to Giα1, Giα2, and Giα3 * , 1999, The Journal of Biological Chemistry.

[28]  T. Fields,et al.  Selective activation of inhibitory G-protein alpha-subunits by partial agonists of the human 5-HT1A receptor. , 1994, Biochemistry.

[29]  P. Leff,et al.  Effector pathway-dependent relative efficacy at serotonin type 2A and 2C receptors: evidence for agonist-directed trafficking of receptor stimulus. , 1998, Molecular pharmacology.

[30]  J. Hagan,et al.  Functional characterisation of the human cloned 5‐HT7 receptor (long form); antagonist profile of SB‐258719 , 1998, British journal of pharmacology.

[31]  B. Kobilka,et al.  G Protein-coupled Receptors , 1998, The Journal of Biological Chemistry.

[32]  H. Bourne,et al.  How receptors talk to trimeric G proteins. , 1997, Current opinion in cell biology.

[33]  A. Brown,et al.  Pharmacological characterisation of [35S]-GTPgammaS binding to Chinese hamster ovary cell membranes stably expressing cloned human 5-HT1D receptor subtypes. , 1995, Journal of receptor and signal transduction research.

[34]  J. Bockaert,et al.  Cloning, expression and pharmacology of the mouse 5‐HT4L receptor , 1996 .

[35]  M. Teitler,et al.  Activating Mutations of the Serotonin 5‐HT2C Receptor , 1997, Journal of neurochemistry.

[36]  M. Simon,et al.  Gα15 and Gα16 Couple a Wide Variety of Receptors to Phospholipase C (*) , 1995, The Journal of Biological Chemistry.

[37]  J. Benovic,et al.  The role of receptor kinases and arrestins in G protein-coupled receptor regulation. , 1998, Annual review of pharmacology and toxicology.

[38]  P. Leff,et al.  A three-state receptor model of agonist action. , 1997, Trends in pharmacological sciences.

[39]  M. Millan,et al.  S 14506: A novel, potent, high‐efficacy 5‐HT1A agonist and potential anxiolytic agent , 1992 .

[40]  B. Kobilka,et al.  GPCR–Gα fusion proteins: molecular analysis of receptor–G-protein coupling , 1999 .

[41]  P. Pauwels,et al.  Interaction of 5-HT1B/D ligands with recombinant h 5-HT1A receptors:Intrinsic activity and modulation by G-protein activation state , 1998, Naunyn-Schmiedeberg's Archives of Pharmacology.

[42]  E. sanders-Bush,et al.  Constitutively active 5-hydroxytryptamine2C receptors reveal novel inverse agonist activity of receptor ligands. , 1994, The Journal of biological chemistry.

[43]  P. Pauwels,et al.  Stimulated [35S]GTPγS binding by 5-HT1A receptor agonists in recombinant cell lines Modulation of apparent efficacy by G-protein activation state , 1997, Naunyn-Schmiedeberg's Archives of Pharmacology.

[44]  C. Niswender,et al.  Serotonin 5‐HT2C Receptor RNA Editing Alters Receptor Basal Activity , 1999, Journal of neurochemistry.

[45]  H Weinstein,et al.  Signal transduction by a 5-HT2 receptor: a mechanistic hypothesis from molecular dynamics simulations of the three-dimensional model of the receptor complexed to ligands. , 1993, Journal of medicinal chemistry.

[46]  D. Lovinger,et al.  Genetic evidence for involvement of multiple effector systems in alpha 2A-adrenergic receptor inhibition of stimulus-secretion coupling. , 1996, Molecular pharmacology.

[47]  J. Bockaert,et al.  Novel brain-specific 5-HT4 receptor splice variants show marked constitutive activity: role of the C-terminal intracellular domain. , 1999, Molecular pharmacology.

[48]  M. Beer,et al.  Characterisation of a cloned human 5-HT1A receptor cell line using [35S]GTPγS binding , 1997 .

[49]  D. Colquhoun,et al.  Binding, gating, affinity and efficacy: The interpretation of structure‐activity relationships for agonists and of the effects of mutating receptors , 1998, British journal of pharmacology.

[50]  G. Milligan,et al.  Inverse agonist-induced up-regulation of the human beta2-adrenoceptor in transfected neuroblastoma X glioma hybrid cells. , 1996, Molecular pharmacology.

[51]  M. Göthert,et al.  Genetic Variation in Human 5‐HT Receptors: Potential Pathogenetic and Pharmacological Role a , 1998, Annals of the New York Academy of Sciences.

[52]  S. Rees,et al.  Hydrophobicity of residue351 of the G protein Gi1 alpha determines the extent of activation by the alpha 2A-adrenoceptor. , 1998, Biochemistry.

[53]  R M Eglen,et al.  7TM receptors: the splicing on the cake. , 1999, Trends in pharmacological sciences.

[54]  P. Pauwels,et al.  How Efficacious are 5-HT1B/D Receptor Ligands: an Answer from GTPγS Binding Studies with Stably Transfected C6-glial Cell Lines , 1997, Neuropharmacology.

[55]  R. Lefkowitz,et al.  A mutation-induced activated state of the beta 2-adrenergic receptor. Extending the ternary complex model. , 1993, The Journal of biological chemistry.

[56]  P. Pauwels,et al.  Modulation of 5-HT1A receptor activation by its interaction with wild-type and mutant Gαi3 proteins , 2001, Neuropharmacology.

[57]  S. Peroutka Serotonin Receptor Variants in Disease: New Therapeutic Opportunities? , 1998, Annals of the New York Academy of Sciences.

[58]  M. Millan,et al.  Inhibition of the constitutive activity of human 5‐HT1A receptors by the inverse agonist, spiperone but not the neutral antagonist, WAY 100,635 , 1997, British journal of pharmacology.

[59]  B. Kobilka,et al.  Fluorescent labeling of purified beta 2 adrenergic receptor. Evidence for ligand-specific conformational changes. , 1995, The Journal of biological chemistry.

[60]  M. Teitler,et al.  Creation of a constitutively activated state of the 5-hydroxytryptamine2A receptor by site-directed mutagenesis: inverse agonist activity of antipsychotic drugs. , 1998, The Journal of pharmacology and experimental therapeutics.

[61]  P. Chidiac,et al.  Inverse agonist activity of beta-adrenergic antagonists. , 1994, Molecular pharmacology.

[62]  R. Emeson,et al.  Regulation of serotonin-2C receptor G-protein coupling by RNA editing , 1997, Nature.

[63]  A. Scheer,et al.  The activation process of the alpha1B-adrenergic receptor: potential role of protonation and hydrophobicity of a highly conserved aspartate. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[64]  D. Selley,et al.  mu-Opioid receptor-stimulated guanosine-5'-O-(gamma-thio)-triphosphate binding in rat thalamus and cultured cell lines: signal transduction mechanisms underlying agonist efficacy. , 1997, Molecular pharmacology.

[65]  R. Graham,et al.  Constitutive activation of a single effector pathway: evidence for multiple activation states of a G protein-coupled receptor. , 1996, Molecular pharmacology.

[66]  M. Caron,et al.  G-protein-coupled receptor regulation: role of G-protein-coupled receptor kinases and arrestins. , 1996, Canadian journal of physiology and pharmacology.

[67]  R. Lefkowitz,et al.  Desensitization of G protein-coupled receptors. , 1996, Recent progress in hormone research.

[68]  R. Lefkowitz,et al.  A ternary complex model explains the agonist-specific binding properties of the adenylate cyclase-coupled beta-adrenergic receptor. , 1980, The Journal of biological chemistry.

[69]  P. Pauwels,et al.  Ligand—Receptor Interactions as Controlled by Wild‐Type and Mutant Thr370Lys α2B‐Adrenoceptor—Gα15 Fusion Proteins , 2000 .

[70]  P. Pauwels,et al.  Facilitation of Constitutive α2A-Adrenoceptor Activity by Both Single Amino Acid Mutation (Thr373Lys) and Gαo Protein Coexpression: Evidence for Inverse Agonism , 2000 .